Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sensei Biotherapeutics, Inc. (SNSE : NSDQ)
 
 • Company Description   
Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company's product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md.

Number of Employees: 56

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.49 Daily Weekly Monthly
20 Day Moving Average: 94,724 shares
Shares Outstanding: 30.63 (millions)
Market Capitalization: $45.64 (millions)
Beta: 0.79
52 Week High: $15.12
52 Week Low: $1.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.40% -15.28%
12 Week -63.75% -60.82%
Year To Date -74.31% -69.57%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
451 D STREET SUITE 710
-
BOSTON,MA 02210
USA
ph: 240-243-8000
fax: -
ir@senseibio.com http://www.senseibio.com
 
 • General Corporate Information   
Officers
John Celebi - Chief Executive Officer and President
William Ringo - Chair
Erin Colgan - Chief Financial Officer
Bob Holmen - Director
James Peyer - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 81728A108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 30.63
Most Recent Split Date: (:1)
Beta: 0.79
Market Capitalization: $45.64 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.64 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.34
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 4.76%
vs. Previous Quarter: -37.93%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -27.48
12/31/21 - -23.14
09/30/21 - -30.07
ROA
03/31/22 - -26.08
12/31/21 - -22.41
09/30/21 - -24.81
Current Ratio
03/31/22 - 18.27
12/31/21 - 30.38
09/30/21 - 30.05
Quick Ratio
03/31/22 - 18.27
12/31/21 - 30.38
09/30/21 - 30.05
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.41
12/31/21 - 4.79
09/30/21 - 5.07
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.01
12/31/21 - 0.01
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 1.35
12/31/21 - 1.13
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©